Every route · Hypercholesterolemia · Heart and circulation

Repatha for Hypercholesterolemia: every route to paying for it

4 of 6 routes have a dated fact in our data for Repatha and Hypercholesterolemia. Where we found nothing the page says so; that does not mean none exists.

The order is fixed and is not a ranking. The FDA label first, then public Medicare facts, then the manufacturer, then charities, then research access. It does not say which route is best for you, and no saving is computed.

A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.

The routes, in order

1
Why this drug and this condition are paired
... cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years ...
From the Indications and Usage text of the drug's FDA label. A label naming a condition is not a statement that the drug is approved, effective or covered for you.
Label on openFDA, read 2026-11-10 · receipt
2
Medicare Part D: the yearly out-of-pocket threshold
Found in our data
CMS prints the Part D out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026).
A benefit parameter of the standard Part D benefit. It applies to covered drugs under plan rules and is not a prediction of what you will pay. Your plan's formulary decides whether this drug is covered: check a formulary.
CMS Table V-2, read 2026-11-08
3
Medicare negotiated price
Not found in our data
This drug is not in the CMS negotiated-price file we hold.
4
Manufacturer and foundation programs
Found in our data
- Repatha Savings (via Amgen) status not recorded
- Heart Medication Assistance (Multiple Programs) status not recorded
- Amgen Safety Net Foundation (the program's own page) receipt
A status is what the program's page says about taking applications, not whether you qualify. Each program has its own eligibility rules.
5
Charitable funds for Hypercholesterolemia
Found in our data
We hold 2 funds for Hypercholesterolemia: 1 open and 1 not open, read 2026-11-08. Open: Hypercholesterolemia from TotalAssist (Patient Advocate Foundation copay funds).
Every fund, with its award level, insurance supported and source, is on the Hypercholesterolemia page. A fund pays for a condition's costs, not necessarily this drug.
6
Clinical trial access
Not found in our data
We hold no trial listing for this ingredient.

More about Repatha and Hypercholesterolemia

Edition 2026-11, root 006ab9a329709cbe. See the licence page.

Questions

Is Repatha approved for Hypercholesterolemia?

This page cannot say that. The Indications and Usage text of the drug's FDA label names Hypercholesterolemia, which is the evidence for pairing them. Read the label and ask your prescriber.

What are the routes on this page?

Why this drug and this condition are paired; Medicare Part D: the yearly out-of-pocket threshold; Medicare negotiated price; Manufacturer and foundation programs; Charitable funds for Hypercholesterolemia; Clinical trial access. For this drug and condition we found why this drug and this condition are paired, medicare part d: the yearly out-of-pocket threshold, manufacturer and foundation programs, charitable funds for hypercholesterolemia and found nothing in our data for medicare negotiated price, clinical trial access.

Is the order a ranking?

No. The order is fixed: the label, then public Medicare facts, then the manufacturer, then charities, then research access. It does not say which route is best or cheapest for you, and no saving is computed.

How current is this?

Each route shows the date we read its source. Statuses are what the source said on that date.